An open label, phase Ib rollover study to assess the long-term safety profile of lapatinib (GW572016) in cancer patients.
Phase of Trial: Phase I
Latest Information Update: 20 Nov 2017
At a glance
- Drugs Lapatinib (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline
- 24 Mar 2010 Additional trial locations (Canada, Israel) identified as reported by ClinicalTrials.gov.
- 24 Mar 2010 Actual end date (May 2009) added as reported by ClinicalTrials.gov.
- 24 Mar 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.